Implementation of European standards of care for cystic fibrosis - Control and treatment of infection

Implementation of European standards of care for cystic fibrosis - Control and treatment of infection
复制标题

DOI:
10.1016/j.jcf.2009.03.001
复制
发表时间:
2009-05-01
影响因子:
5.2
通讯作者:
Bertram, C.
Bertram, C.
中科院分区:
医学2区
文献类型:
--
作者:
Elborn, J. S.;Hodson, M.;Bertram, C.

文献摘要

被引文献

相似文献

背景:囊性纤维化(CF)护理人员存在感染控制和感染治疗的一些指南,尽管实施的程度是可变的。方法:通过向487家欧洲CF中心/单位的指定医疗保健专业人员发送调查问卷,研究CF对欧洲共识指南的依从性。进行定性数据分析。结果:共回收问卷177/547份(32%)。大多数(77%)应答者实施了感染控制政策。分离洋葱伯克霍尔德菌患者在成人(95%)中比儿童(9%)更常见,并且53%的应答者对铜绿假单胞菌进行了分离。雾化粘菌素加口服环丙沙星是铜绿假单胞菌感染最常见的治疗方法(43%)。首次感染铜绿假单胞菌通常采用吸入妥布霉素治疗;41%的受访者直到肺功能恶化才进行干预。大多数急性加重的治疗时间少于推荐的时间。结论:欧洲共识指南被广泛遵守。需要改进的领域包括:及早开始治疗病情恶化,隔离感染患者,优化抗生素治疗的持续时间。(C) 2009年Elsevier B.V.代表欧洲囊性纤维化协会出版。
Background: Several guidelines oil infection control and treatment of infection exist for cystic fibrosis (CF) caregivers, although the extent of implementation is variable.Methods: Adherence to European Consensus Guidelines for CF was Studied by sending surveys to named healthcare professionals in 487 European CF centres/units. Qualitative data analysis was performed.Results: A total of 177/547 (32%) Surveys were returned. Infection control policies were implemented by most (77%) respondents. Separation of patients with Burkholderia cepacia was more common in adults (95%) than children (9%), and was implemented by 53% of respondents for Pseudomonas aeruginosa. Nebulised colistin Plus oral ciprofloxacin was the most common (43%) therapy for P. aeruginosa infection. First infections of P aeruginosa were usually treated with inhaled tobramycin; 41% of repondents did not intervene until lung function deteriorated. Most exacerbations were treated for less than the recommended period.Conclusions: European Consensus Guidelines are widely adhered to. Areas for improvement, include: initiating therapy for exacerbations early, separating infected patients and optimising duration of antibiotic therapy. (C) 2009 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.